Efficacy of three-day course of azithromycin treatment for the bacterial pneumonia in comparison with the ten-day course of co-amoxyclav treatment

Abstract

49 patients with mild or moderate course of bacterial pneumonia were observed. 26 of them were treated with Azythromycin, the other 23 patients were treated with Co-Amoxyclav. The both groups were comparable in respect of the demographic parameters, the disease duration and the previous therapy. More patients with allergic reactions in anamnesis were revealed in the group with Azythromycin treatment (42.3%, p=0.002). All cases of pneumonia were verified by X-ray examination. The examination of all patients included routine ciinical, laboratory and roentgenologic methods for results estimation.
Azythromycin was prescribed in a dose of 500 mg once a day within three days. Co-Amoxyclav was prescribed in a dose of 625 mg three times a day. The both medicines were used per os. The study was completed for all  (26) patients in Azythromycin group. 6 of 23 patients in Co-Amoxyclav group were excluded from the study: 2patients because of antibiotic inefficiency and 4 patients because of side-effects. There were no significant differences between the both groups in the clinical manifestations before the treatment and in 3, 7, 10, 15 days after the therapy beginning. The X-ray examination showed that the infiltration disappeared completely for 92.3% of patients in the Azythromycin group and for 88.2% of patients in the Co-Amoxyclav group. Such allergic reactions as urticaria were the most frequent side-effects developed on the 1-st—7-th day of therapy with Co-Amoxyclav (21.7% of patients).